Prognostic impact of aberrant right hepatic artery involvement in patients with pancreatic cancer: A multicenter retrospective cohort study
Hiroki Ueda MD
Department of Gastroenterological Surgery, Graduate School of Medicine, Osaka University, Suita, Osaka, Japan
Department of Gastroenterological Surgery, Osaka International Cancer Institute, Osaka, Japan
Search for more papers by this authorCorresponding Author
Hidenori Takahashi MD, PhD
Department of Gastroenterological Surgery, Graduate School of Medicine, Osaka University, Suita, Osaka, Japan
Department of Gastroenterological Surgery, Osaka International Cancer Institute, Osaka, Japan
Correspondence Hidenori Takahashi, MD, PhD, Department of Gastroenterological Surgery, Graduate School of Medicine, Osaka University, 2-2 E2, Yamadaoka, Suita, Osaka, 565-0871, Japan; Department of Gastroenterological surgery, Osaka International Cancer Institute, 3-1-69, Otemae, Chuo-ku, Osaka, 541-8567, Japan.
Email: [email protected]
Search for more papers by this authorHirofumi Akita MD, PhD
Department of Gastroenterological Surgery, Osaka International Cancer Institute, Osaka, Japan
Search for more papers by this authorYoshito Tomimaru MD, PhD
Department of Gastroenterological Surgery, Graduate School of Medicine, Osaka University, Suita, Osaka, Japan
Search for more papers by this authorShogo Kobayashi MD, PhD
Department of Gastroenterological Surgery, Graduate School of Medicine, Osaka University, Suita, Osaka, Japan
Search for more papers by this authorMasahiko Kubo MD, PhD
Department of Gastroenterological Surgery, Osaka International Cancer Institute, Osaka, Japan
Search for more papers by this authorYousuke Mukai MD, PhD
Department of Gastroenterological Surgery, Osaka International Cancer Institute, Osaka, Japan
Search for more papers by this authorReishi Toshiyama MD, PhD
Department of Surgery, NHO Osaka National Hospital, Osaka, Japan
Search for more papers by this authorKazuki Sasaki MD, PhD
Department of Gastroenterological Surgery, Graduate School of Medicine, Osaka University, Suita, Osaka, Japan
Search for more papers by this authorShinichiro Hasegawa MD, PhD
Department of Gastroenterological Surgery, Osaka International Cancer Institute, Osaka, Japan
Search for more papers by this authorYoshifumi Iwagami MD, PhD
Department of Gastroenterological Surgery, Graduate School of Medicine, Osaka University, Suita, Osaka, Japan
Search for more papers by this authorKenji Sakai MD, PhD
Department of Surgery, NHO Osaka National Hospital, Osaka, Japan
Search for more papers by this authorDaisaku Yamada MD, PhD
Department of Gastroenterological Surgery, Graduate School of Medicine, Osaka University, Suita, Osaka, Japan
Search for more papers by this authorTakehiro Noda MD, PhD
Department of Gastroenterological Surgery, Graduate School of Medicine, Osaka University, Suita, Osaka, Japan
Search for more papers by this authorTadafumi Asaoka MD, PhD
Department of Gastroenterological Surgery, Osaka Police Hospital, Osaka, Japan
Search for more papers by this authorHiroshi Wada MD, PhD
Department of Gastroenterological Surgery, Osaka International Cancer Institute, Osaka, Japan
Search for more papers by this authorKunihito Gotoh MD, PhD
Department of Surgery, NHO Osaka National Hospital, Osaka, Japan
Search for more papers by this authorYuichiro Doki MD, PhD
Department of Gastroenterological Surgery, Graduate School of Medicine, Osaka University, Suita, Osaka, Japan
Search for more papers by this authorHidetoshi Eguchi MD, PhD
Department of Gastroenterological Surgery, Graduate School of Medicine, Osaka University, Suita, Osaka, Japan
Search for more papers by this authorHiroki Ueda MD
Department of Gastroenterological Surgery, Graduate School of Medicine, Osaka University, Suita, Osaka, Japan
Department of Gastroenterological Surgery, Osaka International Cancer Institute, Osaka, Japan
Search for more papers by this authorCorresponding Author
Hidenori Takahashi MD, PhD
Department of Gastroenterological Surgery, Graduate School of Medicine, Osaka University, Suita, Osaka, Japan
Department of Gastroenterological Surgery, Osaka International Cancer Institute, Osaka, Japan
Correspondence Hidenori Takahashi, MD, PhD, Department of Gastroenterological Surgery, Graduate School of Medicine, Osaka University, 2-2 E2, Yamadaoka, Suita, Osaka, 565-0871, Japan; Department of Gastroenterological surgery, Osaka International Cancer Institute, 3-1-69, Otemae, Chuo-ku, Osaka, 541-8567, Japan.
Email: [email protected]
Search for more papers by this authorHirofumi Akita MD, PhD
Department of Gastroenterological Surgery, Osaka International Cancer Institute, Osaka, Japan
Search for more papers by this authorYoshito Tomimaru MD, PhD
Department of Gastroenterological Surgery, Graduate School of Medicine, Osaka University, Suita, Osaka, Japan
Search for more papers by this authorShogo Kobayashi MD, PhD
Department of Gastroenterological Surgery, Graduate School of Medicine, Osaka University, Suita, Osaka, Japan
Search for more papers by this authorMasahiko Kubo MD, PhD
Department of Gastroenterological Surgery, Osaka International Cancer Institute, Osaka, Japan
Search for more papers by this authorYousuke Mukai MD, PhD
Department of Gastroenterological Surgery, Osaka International Cancer Institute, Osaka, Japan
Search for more papers by this authorReishi Toshiyama MD, PhD
Department of Surgery, NHO Osaka National Hospital, Osaka, Japan
Search for more papers by this authorKazuki Sasaki MD, PhD
Department of Gastroenterological Surgery, Graduate School of Medicine, Osaka University, Suita, Osaka, Japan
Search for more papers by this authorShinichiro Hasegawa MD, PhD
Department of Gastroenterological Surgery, Osaka International Cancer Institute, Osaka, Japan
Search for more papers by this authorYoshifumi Iwagami MD, PhD
Department of Gastroenterological Surgery, Graduate School of Medicine, Osaka University, Suita, Osaka, Japan
Search for more papers by this authorKenji Sakai MD, PhD
Department of Surgery, NHO Osaka National Hospital, Osaka, Japan
Search for more papers by this authorDaisaku Yamada MD, PhD
Department of Gastroenterological Surgery, Graduate School of Medicine, Osaka University, Suita, Osaka, Japan
Search for more papers by this authorTakehiro Noda MD, PhD
Department of Gastroenterological Surgery, Graduate School of Medicine, Osaka University, Suita, Osaka, Japan
Search for more papers by this authorTadafumi Asaoka MD, PhD
Department of Gastroenterological Surgery, Osaka Police Hospital, Osaka, Japan
Search for more papers by this authorHiroshi Wada MD, PhD
Department of Gastroenterological Surgery, Osaka International Cancer Institute, Osaka, Japan
Search for more papers by this authorKunihito Gotoh MD, PhD
Department of Surgery, NHO Osaka National Hospital, Osaka, Japan
Search for more papers by this authorYuichiro Doki MD, PhD
Department of Gastroenterological Surgery, Graduate School of Medicine, Osaka University, Suita, Osaka, Japan
Search for more papers by this authorHidetoshi Eguchi MD, PhD
Department of Gastroenterological Surgery, Graduate School of Medicine, Osaka University, Suita, Osaka, Japan
Search for more papers by this authorAbstract
Background and Objectives
This study aimed to evaluate the prognostic value of aberrant right hepatic artery (A-RHA) involvement in patients with pancreatic cancer (PC).
Methods
This study enrolled 474 patients who underwent upfront pancreatectomy or neoadjuvant treatment for resectable (R) or borderline resectable (BR) PC from four institutions. The patients were divided into three groups: A-RHA involvement group (n = 12), patients who had sole A-RHA involvement without major arterial involvement; BR-A group (n = 104), patients who had major arterial involvement; R/BR-PV group (n = 358), others.
Results
All patients in the A-RHA involvement group underwent margin-negative resection. The median overall survival of the entire cohort in the A-RHA involvement, R/BR-PV, and BR-A groups was 41.2, 33.5, and 25.2 months, respectively. Although survival in the R/BR-PV group was significantly more favorable than that in the BR-A group (p = 0.0003), no significant difference was observed between the A-RHA involvement group and the R/BR-PV (p = 0.7332) and BR-A (p = 0.1485) groups.
Conclusions
The prognosis of patients with PC and sole A-RHA involvement was comparable to that of patients with R/BR-PV.
CONFLICT OF INTEREST STATEMENT
Shogo Kobayashi received honoraria and speaker fees from AstraZeneca, Ethicon Inc., Intuitive, Olympus, and Taiho Pharmaceutical. Other authors do not have conflicts of interest.
Open Research
DATA AVAILABILITY STATEMENT
The data that support the findings of this study are available on request from the corresponding author. The data are not publicly available due to privacy or ethical restrictions. The datasets generated or analyzed during the current study are available from the corresponding author upon reasonable request.
Supporting Information
| Filename | Description |
|---|---|
| jso27792-sup-0001-Figure_S1.docx43.3 KB | Supporting information. |
| jso27792-sup-0002-Figure_S2.docx34.4 KB | Supporting information. |
| jso27792-sup-0003-Supplementary_Table.docx43.4 KB | Supporting information. |
Please note: The publisher is not responsible for the content or functionality of any supporting information supplied by the authors. Any queries (other than missing content) should be directed to the corresponding author for the article.
REFERENCES
- 1Siegel RL, Miller KD, Wagle NS, Jemal A. Cancer statistics, 2023. CA Cancer J Clin. 2023; 73: 17-48.
- 2Rehders A, Stoecklein NH, Güray A, Riediger R, Alexander A, Knoefel WT. Vascular invasion in pancreatic cancer: tumor biology or tumor topography? Surgery. 2012; 152(3 suppl 1): S143-S151.
- 3Ghaneh P, Kleeff J, Halloran CM, et al. The impact of positive resection margins on survival and recurrence following resection and adjuvant chemotherapy for pancreatic ductal adenocarcinoma. Ann Surg. 2019; 269: 520-529.
- 4Bockhorn M, Uzunoglu FG, Adham M, et al. Borderline resectable pancreatic cancer: a consensus statement by the International Study Group of Pancreatic Surgery (ISGPS). Surgery. 2014; 155: 977-988.
- 5Fujii T, Yamada S, Murotani K, et al. Inverse probability of treatment weighting analysis of upfront surgery versus neoadjuvant chemoradiotherapy followed by surgery for pancreatic adenocarcinoma with arterial abutment. Medicine. 2015; 94:e1647.
- 6Murakami Y, Uemura K, Sudo T, et al. Survival impact of neoadjuvant gemcitabine plus S-1 chemotherapy for patients with borderline resectable pancreatic carcinoma with arterial contact. Cancer Chemother Pharmacol. 2017; 79: 37-47.
- 7Sho M, Akahori T, Tanaka T, et al. Importance of resectability status in neoadjuvant treatment for pancreatic cancer. J Hepatobiliary Pancreat Sci. 2015; 22: 563-570.
- 8Noussios G, Dimitriou I, Chatzis I, Katsourakis A. The main anatomic variations of the hepatic artery and their importance in surgical practice: review of the literature. J Clin Med Res. 2017; 9: 248-252.
- 9Zaki SM, Abdelmaksoud AHK, Khaled BEA, Abdel Kader IA. Anatomical variations of hepatic artery using the multidetector computed tomography angiography. Folia Morphol. 2020; 79: 247-254.
- 10Ugurel MS, Battal B, Bozlar U, et al. Anatomical variations of hepatic arterial system, coeliac trunk and renal arteries: an analysis with multidetector CT angiography. Br J Radiol. 2010; 83: 661-667.
- 11Yamaguchi T, Hasegawa K, Sauvain MO, et al. An aberrant right hepatic artery arising from the gastroduodenal artery: a pitfall encountered during pancreaticoduodenectomy. Surg Today. 2021; 51: 1577-1582.
- 12Kim PTW, Temple S, Atenafu EG, et al. Aberrant right hepatic artery in pancreaticoduodenectomy for adenocarcinoma: impact on resectability and postoperative outcomes. HPB. 2014; 16: 204-211.
- 13Miura Y, Ohgi K, Sugiura T, et al. Resectability status of pancreatic cancer having tumor contact with an aberrant right hepatic artery: is upfront surgery justified? Ann Surg Oncol. 2022; 29: 4979-4988.
- 14Turrini O, Wiebke EA, Delpero JR, Viret F, Lillemoe KD, Schmidt CM. Preservation of replaced or accessory right hepatic artery during pancreaticoduodenectomy for adenocarcinoma: impact on margin status and survival. J Gastrointest Surg. 2010; 14: 1813-1819.
- 15Okada K, Kawai M, Hirono S, et al. A replaced right hepatic artery adjacent to pancreatic carcinoma should be divided to obtain R0 resection in pancreaticoduodenectomy. Langenbecks Arch Surg. 2015; 400: 57-65.
- 162023. NCCN Clinical Practice Guidelines in Oncology Pancreatic Adenocarcinoma, version 1.
- 17Isaji S, Mizuno S, Windsor JA, et al. International consensus on definition and criteria of borderline resectable pancreatic ductal adenocarcinoma 2017. Pancreatology. 2018; 18: 2-11.
- 18Tomimaru Y, Tanaka K, Noguchi K, Morita S, Imamura H, Dono K. The branching pattern of the inferior pancreaticoduodenal artery in patients with a replaced right hepatic artery. Am Surg. 2018; 84: 796-800.
- 19Takahashi H, Akita H, Ioka T, et al. Phase I trial evaluating the safety of preoperative gemcitabine/nab-paclitaxel with concurrent radiation therapy for borderline resectable pancreatic cancer. Pancreas. 2018; 47: 1135-1141.
- 20Eguchi H, Takeda Y, Takahashi H, et al. A prospective, open-label, multicenter phase 2 trial of neoadjuvant therapy using full-dose gemcitabine and S-1 concurrent with radiation for resectable pancreatic ductal adenocarcinoma. Ann Surg Oncol. 2019; 26: 4498-4505.
- 21Takahashi H, Ohigashi H, Gotoh K, et al. Preoperative gemcitabine-based chemoradiation therapy for resectable and borderline resectable pancreatic cancer. Ann Surg. 2013; 258: 1040-1050.
- 22Takahashi S, Ohno I, Ikeda M, et al. Neoadjuvant S-1 with concurrent radiotherapy followed by surgery for borderline resectable pancreatic cancer: A phase II open-label multicenter prospective trial (JASPAC05). Ann Surg. 2022; 276: e510-e517.
- 23Katz MHG, Shi Q, Meyers J, et al. Efficacy of preoperative mFOLFIRINOX vs mFOLFIRINOX plus hypofractionated radiotherapy for borderline resectable adenocarcinoma of the pancreas: the A021501 phase 2 randomized clinical trial. JAMA Oncology. 2022; 8: 1263-1270.
- 24Yamada D, Kobayashi S, Takahashi H, et al. Randomized phase II study of gemcitabine and S-1 combination therapy versus gemcitabine and nanoparticle albumin-bound paclitaxel combination therapy as neoadjuvant chemotherapy for resectable/borderline resectable pancreatic ductal adenocarcinoma (PDAC-GS/GA-rP2, CSGO-HBP-015). Trials. 2021; 22: 568.
- 25Ueno H, Ioka T, Ikeda M, et al. Randomized phase III study of gemcitabine plus S-1, S-1 alone, or gemcitabine alone in patients with locally advanced and metastatic pancreatic cancer in Japan and Taiwan: GEST study. J Clin Oncol. 2013; 31: 1640-1648.
- 26Diener MK, Mihaljevic AL, Strobel O, et al. Periarterial divestment in pancreatic cancer surgery. Surgery. 2021; 169: 1019-1025.
- 27Oettle H, Neuhaus P, Hochhaus A, et al. Adjuvant chemotherapy with gemcitabine and long-term outcomes among patients with resected pancreatic cancer: the CONKO-001 randomized trial. JAMA. 2013; 310: 1473-1481.
- 28Uesaka K, Boku N, Fukutomi A, et al. Adjuvant chemotherapy of S-1 versus gemcitabine for resected pancreatic cancer: a phase 3, open-label, randomised, non-inferiority trial (JASPAC 01). The Lancet. 2016; 388: 248-257.
- 29Murakami Y, Satoi S, Sho M, et al. National comprehensive cancer network resectability status for pancreatic carcinoma predicts overall survival. World J Surg. 2015; 39: 2306-2314.
- 30Hayasaki A, Isaji S, Kishiwada M, et al. Survival analysis in patients with pancreatic ductal adenocarcinoma undergoing chemoradiotherapy followed by surgery according to the international consensus on the 2017 definition of borderline resectable cancer. Cancers. 2018; 10: 65.
- 31Kado T, Tomimaru Y, Kobayashi S, et al. Prognostic impact of gastroduodenal artery involvement in cancer of the pancreatic head. Ann Surg Oncol. 2023; 30: 2413-2421.
- 32Imamura T, Yamamoto Y, Sugiura T, et al. Prognostic impact of abutment to the branches of the superior mesenteric artery in borderline resectable pancreatic cancer. Langenbecks Arch Surg. 2020; 405: 939-947.
